APA (7th ed.) Citation

J, L., H, B., JS, W., L, B., M, G., Y, W., . . . K, M. (2021). An open-label phase I dose-escalation study of the safety and pharmacokinetics of DMUC4064A in patients with platinum-resistant ovarian cancer. Gynecologic oncology, 163(3), 473. https://doi.org/10.1016/j.ygyno.2021.09.023

Chicago Style (17th ed.) Citation

J, Liu, et al. "An Open-label Phase I Dose-escalation Study of the Safety and Pharmacokinetics of DMUC4064A in Patients with Platinum-resistant Ovarian Cancer." Gynecologic Oncology 163, no. 3 (2021): 473. https://doi.org/10.1016/j.ygyno.2021.09.023.

MLA (9th ed.) Citation

J, Liu, et al. "An Open-label Phase I Dose-escalation Study of the Safety and Pharmacokinetics of DMUC4064A in Patients with Platinum-resistant Ovarian Cancer." Gynecologic Oncology, vol. 163, no. 3, 2021, p. 473, https://doi.org/10.1016/j.ygyno.2021.09.023.